Abstract 96P
Background
PD-1 blockade alone in heavily treated MSS/pMMR mCRC patients (pts) is ineffective. PD-1 blockade combined with antiangiogenic therapy has synergistic effects and has shown clinical benefits in several trials. TRAP aims to explore the efficacy and safety of TKIs combined with PD-1 blockade in TKI-responsive MSS/pMMR mCRC pts refractory to standard chemotherapy with or without anti-VEGF and/or anti-EGFR therapies. Here we report the updated results at the data cutoff of Feb 6, 2023.
Methods
Eligible pts were given 1 cycle of TKIs (fruquintinib 5mg or regorafenib 120mg, d1-21, q4w) and grouped by tumor response according to RECIST v1.1: arm A: reduction of target lesion to CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic target lesions ≥15%; arm B: enlarged SD; arm C: PD. Then arm B pts were given another cycle of TKIs and grouped again. Pts in arm A then received TKIs plus anti-PD-1 antibody (toripalimab 240mg, or sintilimab 200mg, i.v.gtt, q3w, until PD or up to 2 years), pts in arm B continued with TKIs until PD. The Simon 2-stage design tested the null 9-months (m) PFS rate of 27.1% vs. 55% (power = 0.90; α = 0.05). A total of >10 pts reaching ≥ 9-m PFS in 25 pts receiving TKI plus anti-PD-1 antibody is required to reject null hypothesis.
Results
49 pts were enrolled. Median age, 59 (34-72); male, 51.0%; ECOG PS 1, 100%; median prior regimens, 2 (1-4). 20 entered arm A in 46 evaluable pts. All pts in arm A had prior 5-FU and oxaliplatin, 85.0% had prior anti-VEGF and/or anti-EGFR therapies. In arm A, ORR was 15.0%, median follow-up was 21.6m, mPFS was 13.2m (95% CI, 8.95m-NA), 6-m, 9-m and 12-m PFS rates were 88.8% (95%CI, 75.3%-100%), 66.6% (95%CI, 46.2%-96.0%) and 50.8% (95%CI, 29.9%-86.0%). OS was not mature. The most common treatment-related adverse events (TRAEs) (total; Grade ≥3) were hand-foot skin reaction (43.8%; 18.8%), hypothyroidism (37.5%; 6.3%), hypertension (31.2%; 25.0%) and proteinuria (31.2%; 6.3%). No treatment related death was observed.
Conclusions
TKIs combined with PD-1 blockade has shown encouraging efficacy with acceptable toxicities in MSS/pMMR mCRC pts responsive to TKI treatment.
Clinical trial identification
NCT04483219.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract